1
|
Cohen SB, Dabi Y, Burke Y, Mamadov N, Manoim N, Mashiach R, Berkowitz E, Bouaziz J, Nicolas-Boluda A, Grazia Porpora M, Ziv-Baran T. Laparoscopic nerve lysis for deep endometriosis improves quality of life and chronic pain levels: A pilot study. J Gynecol Obstet Hum Reprod 2024; 53:102778. [PMID: 38570115 DOI: 10.1016/j.jogoh.2024.102778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2024] [Revised: 03/21/2024] [Accepted: 03/22/2024] [Indexed: 04/05/2024]
Abstract
OBJECTIVES To assess the benefit of surgical management of patients with endometriosis infiltrating pelvic nerves in terms of pain, analgesic consumption, and quality of life (QOL). METHODS We conducted a retrospective cohort study In an Endometriosis referral center at a tertiary care university affiliated medical center. Patients diagnosed with endometriosis that underwent laparoscopic neurolysis for chronic pain were included. Patients rated their pain before and after surgery and differentiated between chronic pain and acute crises. Patients were requested to maintain a record of analgesic consumption and to evaluate their quality-of-life (QOL). RESULTS Of the 21 patients in our study 15 (71.5 %) had obturator nerve involvement, 2 (9.5 %) had pudendal nerve involvement and 4 (19 %) had other pelvic nerve involvement. Median postoperative follow - up was of 8 months. All but 2 patients (9.6 %) had significant chronic pain improvement with a mean decrease of VAS of 3.05 (±2.5). Analgesic habits changed postoperatively with a significant decrease of 66 % of patients' daily consumption of any analgesics. Surgery improved QOL in 12 cases (57.1 %) and two patients (9.6 %) completely recovered with a high QOL. CONCLUSION Neurolysis and excision of endometriosis of pelvic nerves could results in significant improvement of quality of life.
Collapse
Affiliation(s)
- Shlomo B Cohen
- Endometriosis and Chronic Pelvic Pain Unit, Department of obstetrics and gynecology, Sheba Medical Center, Ramat Gan, Israel and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Yohann Dabi
- Sorbonne University,Department of obstetrics and gynecology Tenon Hospital (AP-HP), Paris, France.
| | - Yechiel Burke
- Endometriosis and Chronic Pelvic Pain Unit, Department of obstetrics and gynecology, Sheba Medical Center, Ramat Gan, Israel and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Nicole Mamadov
- Endometriosis and Chronic Pelvic Pain Unit, Department of obstetrics and gynecology, Sheba Medical Center, Ramat Gan, Israel and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Nir Manoim
- Endometriosis and Chronic Pelvic Pain Unit, Department of obstetrics and gynecology, Sheba Medical Center, Ramat Gan, Israel and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Roy Mashiach
- Endometriosis and Chronic Pelvic Pain Unit, Department of obstetrics and gynecology, Sheba Medical Center, Ramat Gan, Israel and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Elad Berkowitz
- Endometriosis and Chronic Pelvic Pain Unit, Department of obstetrics and gynecology, Sheba Medical Center, Ramat Gan, Israel and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
| | - Jerome Bouaziz
- Department of Research, One Clinic, 25 Boulevard Pasteur, 75015 Paris, France
| | - Alba Nicolas-Boluda
- Department of Research, One Clinic, 25 Boulevard Pasteur, 75015 Paris, France
| | | | - Tomer Ziv-Baran
- Department of Epidemiology and Preventive Medicine, School of Public Health, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
2
|
Dabi Y, Bouaziz J, Burke Y, Nicolas-Boluda A, Cordier AG, Chayo J, Cohen SB. Outcome of subsequent pregnancies post uterine rupture in previous delivery: A case series, a review, and recommendations for appropriate management. Int J Gynaecol Obstet 2023; 161:204-217. [PMID: 36087068 DOI: 10.1002/ijgo.14445] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2022] [Revised: 08/20/2022] [Accepted: 08/30/2022] [Indexed: 11/08/2022]
Abstract
OBJECTIVES To provide clinicians with concrete solutions on the best management of and counseling for patients in a subsequent pregnancy following uterine rupture. METHODS A retrospective analysis of patients treated between 2005 and 2020 at Sheba Medical Center was conducted. All patients who had undergone a complete uterine rupture and subsequently had a full-term pregnancy were included. A literature review was conducted using Pubmed database and including previously published literature reviews. RESULTS Fifteen patients with subsequent pregnancies following uterine rupture were included in our cohort. Mean interval between rupture and subsequent pregnancy was 3.8 years (range 2.2-6.9 years). One patient had repeat uterine rupture of less than 2 cm at 36+5 weeksof pregnancy. A total of 17 studies were selected in this literature review, including a total of 774 pregnancies in 635 patients. The risk of repeated uterine rupture was 8.0% (62/774), ranging from 0% to 37.5%. Overall, the risk of maternal death was of 0.6% (4/635), with only four cases reported in three studies. CONCLUSION The risk of recurrence after uterine rupture is significant but should not prevent patients from conceiving.
Collapse
Affiliation(s)
- Yohann Dabi
- PointGyn-Gynecologic and Obstetrics Department, Paris, France.,Department of Research, One Clinic, Paris, France
| | - Jerome Bouaziz
- PointGyn-Gynecologic and Obstetrics Department, Paris, France.,Department of Research, One Clinic, Paris, France
| | - Yechiel Burke
- Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel
| | - Alba Nicolas-Boluda
- PointGyn-Gynecologic and Obstetrics Department, Paris, France.,Department of Research, One Clinic, Paris, France
| | - Anne-Gael Cordier
- Sorbonne University, Department of Obstetrics and Gynecology, Tenon Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France
| | - Jennifer Chayo
- Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel
| | - Shlomo B Cohen
- Department of Obstetrics and Gynecology, Sheba Medical Center, Tel Hashomer, Israel
| |
Collapse
|
3
|
Ponzo M, Debesset A, Cossutta M, Chalabi-Dchar M, Houppe C, Pilon C, Nicolas-Boluda A, Meunier S, Raineri F, Thiolat A, Nicolle R, Maione F, Brundu S, Cojocaru CF, Bouvet P, Bousquet C, Gazeau F, Tournigand C, Courty J, Giraudo E, Cohen JL, Cascone I. Correction: Ponzo et al. Nucleolin Therapeutic Targeting Decreases Pancreatic Cancer Immunosuppression. Cancers 2022 , 14, 4265. Cancers (Basel) 2022; 14:cancers14246160. [PMID: 36551754 PMCID: PMC9776549 DOI: 10.3390/cancers14246160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2022] [Accepted: 11/23/2022] [Indexed: 12/15/2022] Open
Abstract
In the original publication [...].
Collapse
Affiliation(s)
- Matteo Ponzo
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Anais Debesset
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Mélissande Cossutta
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Mounira Chalabi-Dchar
- Cancer Research Center of Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, F-69008 Lyon, France
| | - Claire Houppe
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Caroline Pilon
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D’investigation Clinique Biothérapie, F-94010 Créteil, France
| | - Alba Nicolas-Boluda
- Matières et Systèmes Complexes (MSC), Université de Paris, CNRS UMR 7057, F-75006 Paris, France
| | - Sylvain Meunier
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Fabio Raineri
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Allan Thiolat
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
| | - Rémy Nicolle
- Programme Cartes d’Identité des Tumeurs (CIT), Ligue Nationale Contre le Cancer, F-75013 Paris, France
| | - Federica Maione
- Laboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy
- Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy
| | - Serena Brundu
- Laboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy
- Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy
| | - Carina Florina Cojocaru
- Laboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy
- Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy
| | - Philippe Bouvet
- Matières et Systèmes Complexes (MSC), Université de Paris, CNRS UMR 7057, F-75006 Paris, France
- Ecole Normale Supérieure de Lyon, University of Lyon, F-69342 Lyon, France
| | - Corinne Bousquet
- UMR INSERM-1037, Cancer Research Center of Toulouse (CRCT), Toulouse University III, F-31037 Toulouse, France
| | - Florence Gazeau
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D’investigation Clinique Biothérapie, F-94010 Créteil, France
| | - Christophe Tournigand
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- AP-HP, Service d’Oncologie Médicale, Groupe Hospitalo-Universitaire Chenevier Mondor, F-94010 Créteil, France
| | - José Courty
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- Cancer Research Center of Lyon, Cancer Cell Plasticity Department, University of Lyon, UMR INSERM 1052 CNRS 5286, Centre Léon Bérard, F-69008 Lyon, France
| | - Enrico Giraudo
- Laboratory of Tumor Microenvironment, Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, Italy
- Department of Science and Drug Technology, University of Torino, 10125 Torino, Italy
| | - José L. Cohen
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D’investigation Clinique Biothérapie, F-94010 Créteil, France
| | - Ilaria Cascone
- Immune Regulation and Biotherapy, Inserm U955, IMRB University of Paris-Est Creteil (UPEC) 8, INSERM, IMRB, F-94010 Créteil, France
- AP-HP, Groupe Hospitalo-Universitaire Chenevier Mondor, Centre D’investigation Clinique Biothérapie, F-94010 Créteil, France
- Correspondence: ; Tel.: +33-149-813-765
| |
Collapse
|
4
|
Nicolas-Boluda A, Laurent G, Bazzi R, Roux S, Donnadieu E, Gazeau F. Two step promotion of a hot tumor immune environment by gold decorated iron oxide nanoflowers and light-triggered mild hyperthermia. Nanoscale 2021; 13:18483-18497. [PMID: 34752596 DOI: 10.1039/d1nr03201a] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
Nanoparticle-mediated photothermal therapy (PTT) is an emerging modality to treat tumors with both spatial and temporal control provided by light activation. Gold decorated iron oxide nanoflowers (GIONF) are good candidates for PTT due to their biocompatibility, biodegradability and light-to-heat conversion. Profound changes in the tumor immune environment might be early induced by the gold and iron oxide metallic agents in addition to the photothermal effects. This study aims to elucidate the outcome of GIONF on their own, and of GIONF-induced mild hyperthermia in the tumor immune infiltrate in a murine model of triple negative breast cancer. First we explored the effects of 24 h GIONF exposure on bone-marrow derived macrophages (BMDM), revealing significant effects on the BMDM phenotype and secretion, 6 days post-incubation, with important downregulation of several cytokines and MHCII expression, predominantly towards a pro-inflammatory response. Intratumoral administration of GIONF promoted an increase in monocyte recruitment at day 1 post-administration, shifting towards a pro-inflammatory anti-tumor microenvironment with lower Treg population and a 4 fold lower CD4/CD8 ratio compared to the control at day 12. On top of the GIONF effects, mild hyperthermia (43 °C for 15 min), although it does not induce significant changes in tumor growth, resulted in an additional increase of CD8+ T lymphocytes and pro-inflammatory cytokines. The combination of a timely controlled immune response to GIONF and to mild hyperthermia could be used as a remotely triggered adjuvant treatment to immunotherapy approaches at the best favorable time-window.
Collapse
Affiliation(s)
- Alba Nicolas-Boluda
- Université de Paris, MSC, CNRS-UMR 7057, Paris, France.
- Université de Paris, Institut Cochin, INSERM U1016/CNRS UMR 8104, Paris, France
| | - Gautier Laurent
- Institut UTINAM, CNRS UMR 6213, Université Bourgogne Franche-Comté, Besançon, France
| | - Rana Bazzi
- Institut UTINAM, CNRS UMR 6213, Université Bourgogne Franche-Comté, Besançon, France
| | - Stéphane Roux
- Institut UTINAM, CNRS UMR 6213, Université Bourgogne Franche-Comté, Besançon, France
| | - Emmanuel Donnadieu
- Université de Paris, Institut Cochin, INSERM U1016/CNRS UMR 8104, Paris, France
| | | |
Collapse
|
5
|
Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C, Ponzo M, Renault G, Deptula P, Pogoda K, Bucki R, Cascone I, Courty J, Fouassier L, Gazeau F, Donnadieu E. Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. eLife 2021; 10:58688. [PMID: 34106045 PMCID: PMC8203293 DOI: 10.7554/elife.58688] [Citation(s) in RCA: 105] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2020] [Accepted: 06/05/2021] [Indexed: 12/17/2022] Open
Abstract
Only a fraction of cancer patients benefits from immune checkpoint inhibitors. This may be partly due to the dense extracellular matrix (ECM) that forms a barrier for T cells. Comparing five preclinical mouse tumor models with heterogeneous tumor microenvironments, we aimed to relate the rate of tumor stiffening with the remodeling of ECM architecture and to determine how these features affect intratumoral T cell migration. An ECM-targeted strategy, based on the inhibition of lysyl oxidase, was used. In vivo stiffness measurements were found to be strongly correlated with tumor growth and ECM crosslinking but negatively correlated with T cell migration. Interfering with collagen stabilization reduces ECM content and tumor stiffness leading to improved T cell migration and increased efficacy of anti-PD-1 blockade. This study highlights the rationale of mechanical characterizations in solid tumors to understand resistance to immunotherapy and of combining treatment strategies targeting the ECM with anti-PD-1 therapy.
Collapse
Affiliation(s)
- Alba Nicolas-Boluda
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France.,Laboratoire Matière et Systèmes Complexes (MSC), CNRS, Université de Paris, Paris, France
| | - Javier Vaquero
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, France.,TGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.,LPP (Laboratoire de physique des plasmas, UMR 7648), Sorbonne Université, Centre national de la recherche scientifique (CNRS), Ecole Polytechnique, Paris, France.,Oncology Program, CIBEREHD, National Biomedical Research Institute on Liver and Gastrointestinal Diseases, Instituto de Salud Carlos III, Barcelona, Spain
| | - Lene Vimeux
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Thomas Guilbert
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France
| | - Sarah Barrin
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Chahrazade Kantari-Mimoun
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| | - Matteo Ponzo
- CNRS ERL 9215, CRRET laboratory, University of Paris-Est Créteil (UPEC), Paris, France
| | - Gilles Renault
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France
| | - Piotr Deptula
- Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, Białystok, Poland
| | - Katarzyna Pogoda
- Institute of Nuclear Physics, Polish Academy of Sciences, Kraków, Poland
| | - Robert Bucki
- Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Białystok, Białystok, Poland
| | - Ilaria Cascone
- CNRS ERL 9215, CRRET laboratory, University of Paris-Est Créteil (UPEC), Paris, France
| | - José Courty
- CNRS ERL 9215, CRRET laboratory, University of Paris-Est Créteil (UPEC), Paris, France
| | - Laura Fouassier
- Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, Paris, France
| | - Florence Gazeau
- Laboratoire Matière et Systèmes Complexes (MSC), CNRS, Université de Paris, Paris, France
| | - Emmanuel Donnadieu
- Institut Cochin, INSERM U1016/CNRS UMR 8104, Université de Paris, Paris, France.,Equipe Labellisée Ligue Contre le Cancer, Paris, France
| |
Collapse
|
6
|
Fétiveau L, Paul G, Nicolas-Boluda A, Volatron J, George R, Laurent S, Muller R, Sancey L, Mejanelle P, Gloter A, Gazeau F, Catala L. Tailored ultra-small Prussian blue-based nanoparticles for MRI imaging and combined photothermal/photoacoustic theranostics. Chem Commun (Camb) 2020; 55:14844-14847. [PMID: 31768507 DOI: 10.1039/c9cc07116d] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
Abstract
Ultrasmall sub-10 nm nanoparticles of Prussian blue analogues incorporating GdIII ions at their periphery revealed longitudinal relaxivities above 40 mM-1 s-1 per GdIII regardless of the nature of the core and the polymer coating. Large T1-weighted contrast enhancements were achieved in addition to a highly efficient photothermal effect and in vivo photoacoustic imaging in tumors.
Collapse
Affiliation(s)
- Lucile Fétiveau
- Institut de Chimie Moléculaire et des Matériaux d'Orsay, CNRS, Université Paris Sud Paris Saclay, 91405 Orsay, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Nicolas-Boluda A, Donnadieu E. Obstacles to T cell migration in the tumor microenvironment. Comp Immunol Microbiol Infect Dis 2018; 63:22-30. [PMID: 30961814 DOI: 10.1016/j.cimid.2018.12.006] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Revised: 11/27/2018] [Accepted: 12/20/2018] [Indexed: 12/21/2022]
Abstract
These last years, significant progress has been made in the design of strategies empowering T cells with efficient anti-tumor activities. Hence, adoptive T cell therapy and the use of monoclonal antibodies against the immunosuppressive surface molecules CTLA-4 and PD-1 appear as the most promising immunotherapies against cancer. One of the challenges ahead is to render these therapeutic interventions even more effective as a still elevated fraction of cancer patients is refractory to these treatments. A frequently overlooked determinant of the success of T cell-based immunotherapy relates to the ability of effector T cells to migrate into and within tumors, as well as to have access to tumor antigens. Here, we will focus on recent advances in understanding T cell trafficking into and within tumors. Both chemoattractant molecules and structural determinants are essential for regulating T cell motile behavior along with cellular interactions-mediated antigen recognition. In addition, we will review evidence that the microenvironment of advanced tumors creates multiple obstacles limiting T cells from migrating and making contact with their malignant targets. We will particularly focus on the extracellular matrix and tumor-associated macrophages that make tumors a hostile environment for T cell ability to contact and kill malignant cells. Finally, we will discuss possible strategies to restore a tumor microenvironment more favorable to T cell migration and functions with a special emphasis on approaches targeting the dysregulated extracellular matrix of growing tumors.
Collapse
Affiliation(s)
- Alba Nicolas-Boluda
- Inserm, U1016, Institut Cochin, Paris, France; Cnrs, UMR8104, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Emmanuel Donnadieu
- Inserm, U1016, Institut Cochin, Paris, France; Cnrs, UMR8104, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
| |
Collapse
|
8
|
Nicolas-Boluda A, Silva AK, Fournel S, Gazeau F. Physical oncology: New targets for nanomedicine. Biomaterials 2018; 150:87-99. [DOI: 10.1016/j.biomaterials.2017.10.014] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2017] [Revised: 09/28/2017] [Accepted: 10/02/2017] [Indexed: 02/07/2023]
|
9
|
Kolosnjaj-Tabi J, Marangon I, Nicolas-Boluda A, Silva AKA, Gazeau F. Nanoparticle-based hyperthermia, a local treatment modulating the tumor extracellular matrix. Pharmacol Res 2017; 126:123-137. [PMID: 28720518 DOI: 10.1016/j.phrs.2017.07.010] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/25/2017] [Revised: 06/02/2017] [Accepted: 07/11/2017] [Indexed: 02/08/2023]
Abstract
The structural complexity and physical properties of the tumor microenvironment negatively affect the penetration and efficiency of conventional anticancer drugs. While previously underestimated, the tumor microenvironment now becomes a potential target for cancer treatment. This microenvironment can be modulated either systemically by pharmacological means, or locally, through physical effects mediated by certain nanoparticles. Some of them, such as magnetic, plasmonic or carbon-based nanoparticles, can generate heat on demand in a spatially and temporally controlled manner. In addition, the nanoparticles can be either activated by light or magnetic stimuli. The impact of the resulting local heating can be observed on the ultrastructural level, as it strongly affects the organization of collagen fibers, and on the macroscopic level, since the thermal damages alter the mechanical properties of the tumor. Nanoparticle-based hyperthermia thus improves the effect of conventional anticancer drugs, as it allows their better penetration through the altered extracellular matrix. Here we suggest the use of nanoparticle-generated hyperthermia, obtained after magnetic or light activation, as an adjuvant treatment to prime the tumor microenvironment and improve the efficacy of chemotherapy.
Collapse
Affiliation(s)
- Jelena Kolosnjaj-Tabi
- Laboratoire Matière et Systèmes Complexes (MSC), CNRS-UMR 7057, Université Paris Diderot, Sorbonne Paris Cité, 10 rue Alice Domon et Léonie Duquet, F-75205 Paris Cedex 13, France
| | - Iris Marangon
- Laboratoire Matière et Systèmes Complexes (MSC), CNRS-UMR 7057, Université Paris Diderot, Sorbonne Paris Cité, 10 rue Alice Domon et Léonie Duquet, F-75205 Paris Cedex 13, France
| | - Alba Nicolas-Boluda
- Laboratoire Matière et Systèmes Complexes (MSC), CNRS-UMR 7057, Université Paris Diderot, Sorbonne Paris Cité, 10 rue Alice Domon et Léonie Duquet, F-75205 Paris Cedex 13, France
| | - Amanda K A Silva
- Laboratoire Matière et Systèmes Complexes (MSC), CNRS-UMR 7057, Université Paris Diderot, Sorbonne Paris Cité, 10 rue Alice Domon et Léonie Duquet, F-75205 Paris Cedex 13, France
| | - Florence Gazeau
- Laboratoire Matière et Systèmes Complexes (MSC), CNRS-UMR 7057, Université Paris Diderot, Sorbonne Paris Cité, 10 rue Alice Domon et Léonie Duquet, F-75205 Paris Cedex 13, France.
| |
Collapse
|
10
|
Silva AK, Nicolas-Boluda A, Fouassier L, Gazeau F. Overcoming the tumor microenvironment: the role of nanohyperthermia. Nanomedicine (Lond) 2017; 12:1213-1215. [DOI: 10.2217/nnm-2017-0096] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Affiliation(s)
- Amanda K Silva
- Laboratoire Matière et Systèmes Complexes (MSC), CNRS-UMR 7057, Université Paris Diderot, Sorbonne Paris Cité, 10 rue Alice Domon et Léonie Duquet, F-75205, Paris Cedex 13, France
| | - Alba Nicolas-Boluda
- Laboratoire Matière et Systèmes Complexes (MSC), CNRS-UMR 7057, Université Paris Diderot, Sorbonne Paris Cité, 10 rue Alice Domon et Léonie Duquet, F-75205, Paris Cedex 13, France
| | - Laura Fouassier
- Sorbonne Universités, UPMC Université Paris 6, INSERM, Saint-Antoine Research Center, F-75012, Paris, France
| | - Florence Gazeau
- Laboratoire Matière et Systèmes Complexes (MSC), CNRS-UMR 7057, Université Paris Diderot, Sorbonne Paris Cité, 10 rue Alice Domon et Léonie Duquet, F-75205, Paris Cedex 13, France
| |
Collapse
|